Market Cap ₹3120 Cr.
Stock P/E -20.2
P/B 0.5
Current Price ₹199
Book Value ₹ 364.3
Face Value 2
52W High ₹283
Dividend Yield 0%
52W Low ₹ 113.3
Dishman Carbogen Amicis Ltd is an totally India-based contract research and manufacturing offerings (CRAMS) employer. The Company is engaged in the process of R&D to late-stage clinical and commercial manufacturing. It operates thru 2 segments: CRAMS and Others. The CRAMS segment is its agreement research and production segment below the long-term supply agreements. The others section is centred on bulk tablets, intermediates, quaternary ammonium compounds (Quats) and chemical substances and outsourced/traded goods. It manufactures segment transfer catalysts, intermediates, fine chemical substances, and various merchandise for pharmaceutical, cosmetic and associated industries. It additionally manufactures and elements various Vitamin D and Vitamin D analogues. It additionally manufactures cholesterol and lanolin related merchandise for pharmaceutical, beauty and related markets. The Company operates through nine production sites in Europe, India, China and Saudi Arabia.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 459 | 562 | 569 | 541 | 614 | 640 | 619 | 723 | 587 | 651 |
| Other Income | 10 | 19 | 4 | 6 | 9 | 7 | 7 | 7 | 8 | 6 |
| Total Income | 469 | 581 | 573 | 546 | 623 | 646 | 625 | 730 | 595 | 657 |
| Total Expenditure | 360 | 453 | 547 | 452 | 535 | 526 | 567 | 602 | 526 | 610 |
| Operating Profit | 109 | 129 | 26 | 94 | 87 | 120 | 58 | 128 | 69 | 47 |
| Interest | 14 | 15 | 16 | 19 | 20 | 22 | 24 | 28 | 27 | 33 |
| Depreciation | 74 | 75 | 84 | 75 | 80 | 50 | 76 | 70 | 75 | 80 |
| Exceptional Income / Expenses | -3 | 0 | -12 | 0 | 0 | -3 | -46 | 0 | -3 | 0 |
| Profit Before Tax | 19 | 38 | -85 | -0 | -12 | 46 | -88 | 29 | -36 | -66 |
| Provision for Tax | 7 | 3 | -41 | -4 | -2 | -1 | -17 | 12 | 5 | -7 |
| Profit After Tax | 11 | 35 | -45 | 4 | -10 | 47 | -71 | 17 | -41 | -60 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 11 | 35 | -45 | 4 | -10 | 47 | -71 | 17 | -41 | -60 |
| Adjusted Earnings Per Share | 0.7 | 2.3 | -2.8 | 0.3 | -0.6 | 3 | -4.5 | 1.1 | -2.6 | -3.8 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|
| Net Sales | 1714 | 1695 | 2059 | 2044 | 1912 | 2141 | 2413 | 2580 |
| Other Income | 26 | 53 | 54 | 44 | 39 | 49 | 28 | 28 |
| Total Income | 1740 | 1748 | 2112 | 2088 | 1951 | 2190 | 2441 | 2607 |
| Total Expenditure | 1260 | 1257 | 1507 | 1546 | 1638 | 1815 | 2081 | 2305 |
| Operating Profit | 479 | 491 | 606 | 542 | 313 | 375 | 360 | 302 |
| Interest | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 112 |
| Depreciation | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 301 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -22 | -15 | -48 | -49 |
| Profit Before Tax | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -161 |
| Provision for Tax | 71 | 76 | 98 | 39 | 100 | -22 | -25 | -7 |
| Profit After Tax | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -155 |
| Adjustments | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 161 | 155 | 210 | 159 | -165 | 18 | -30 | -155 |
| Adjusted Earnings Per Share | 0 | 9.6 | 13 | 10.1 | -10.5 | 1.1 | -1.9 | -9.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 13% | 6% | 7% | 0% |
| Operating Profit CAGR | -4% | -13% | -6% | 0% |
| PAT CAGR | -267% | NAN% | NAN% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 60% | 1% | -1% | NA% |
| ROE Average | -1% | -1% | 1% | 523% |
| ROCE Average | 0% | 0% | 2% | 3% |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 4814 | 5107 | 5379 | 5715 | 5699 | 5549 | 5810 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 460 | 525 | 362 | 241 | 504 | 762 | 1047 |
| Other Non-Current Liabilities | 307 | 359 | 381 | 668 | 863 | 904 | 785 |
| Total Current Liabilities | 994 | 1178 | 1198 | 1569 | 1290 | 1420 | 1798 |
| Total Liabilities | 6574 | 7169 | 7321 | 8193 | 8356 | 8634 | 9439 |
| Fixed Assets | 4847 | 5061 | 5092 | 5673 | 5693 | 5768 | 6183 |
| Other Non-Current Assets | 394 | 562 | 675 | 742 | 958 | 1027 | 1338 |
| Total Current Assets | 1333 | 1546 | 1554 | 1779 | 1704 | 1839 | 1918 |
| Total Assets | 6574 | 7169 | 7321 | 8193 | 8356 | 8634 | 9439 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 59 | 66 | 76 | 122 | 244 | 110 |
| Cash Flow from Operating Activities | 303 | 226 | 282 | 585 | 513 | 355 | 220 |
| Cash Flow from Investing Activities | -142 | -297 | -169 | -442 | -380 | -619 | -448 |
| Cash Flow from Financing Activities | -137 | 78 | -102 | -98 | -11 | 130 | 250 |
| Net Cash Inflow / Outflow | 23 | 7 | 11 | 46 | 122 | -133 | 22 |
| Closing Cash & Cash Equivalent | 59 | 66 | 76 | 122 | 244 | 110 | 132 |
| # | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 9.58 | 13.03 | 10.1 | -10.53 | 1.15 | -1.9 |
| CEPS(Rs) | 0 | 22.68 | 27.93 | 28.13 | 9.11 | 20.77 | 16 |
| DPS(Rs) | 0 | 0 | 0.2 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0 | 316.44 | 333.28 | 364.25 | 363.45 | 353.89 | 370.51 |
| Core EBITDA Margin(%) | 26.45 | 25.85 | 26.81 | 24.35 | 14.34 | 15.21 | 13.77 |
| EBIT Margin(%) | 15.47 | 16.5 | 17.75 | 12.68 | -0.91 | 2.46 | 1.29 |
| Pre Tax Margin(%) | 12.61 | 13.62 | 15 | 9.65 | -3.4 | -0.2 | -2.26 |
| PAT Margin (%) | 8.49 | 9.12 | 10.22 | 7.76 | -8.64 | 0.84 | -1.24 |
| Cash Profit Margin (%) | 20.94 | 21.6 | 21.89 | 21.6 | 7.47 | 15.21 | 10.4 |
| ROA(%) | 2.21 | 2.25 | 2.9 | 2.04 | -2 | 0.21 | -0.33 |
| ROE(%) | 3654.02 | 6.05 | 4.01 | 2.86 | -2.89 | 0.32 | -0.52 |
| ROCE(%) | 4.6 | 4.67 | 5.79 | 3.93 | -0.26 | 0.76 | 0.43 |
| Receivable days | 60.82 | 78.6 | 78.87 | 91.33 | 95.27 | 76.23 | 80.42 |
| Inventory Days | 90.86 | 98.11 | 91.59 | 100.87 | 104.66 | 98.96 | 109.59 |
| Payable days | 94.92 | 147.09 | 171.97 | 190.21 | 176.5 | 147.9 | 147.42 |
| PER(x) | 0 | 33.48 | 16.07 | 5.31 | 0 | 161.2 | 0 |
| Price/Book(x) | 0 | 1.01 | 0.63 | 0.15 | 0.3 | 0.52 | 0.34 |
| Dividend Yield(%) | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.5 | 3.66 | 2.1 | 0.85 | 1.34 | 1.94 | 1.49 |
| EV/Core EBITDA(x) | 1.8 | 12.63 | 7.14 | 3.2 | 8.21 | 11.08 | 9.97 |
| Net Sales Growth(%) | 0 | -1.1 | 21.47 | -0.73 | -6.44 | 11.96 | 12.72 |
| EBIT Growth(%) | 0 | 5.48 | 30.66 | -29.07 | -106.72 | 401.72 | -40.83 |
| PAT Growth(%) | 0 | 6.28 | 36.07 | -24.64 | -204.18 | 110.91 | -265.46 |
| EPS Growth(%) | 0 | 0 | 36.07 | -22.48 | -204.24 | 110.91 | -265.46 |
| Debt/Equity(x) | 238.62 | 0.21 | 0.19 | 0.18 | 0.2 | 0.26 | 0.31 |
| Current Ratio(x) | 1.34 | 1.31 | 1.3 | 1.13 | 1.32 | 1.3 | 1.07 |
| Quick Ratio(x) | 0.91 | 0.9 | 0.84 | 0.76 | 0.92 | 0.84 | 0.62 |
| Interest Cover(x) | 5.41 | 5.73 | 6.46 | 4.18 | -0.37 | 0.93 | 0.36 |
| Total Debt/Mcap(x) | 0 | 0.21 | 0.31 | 1.25 | 0.68 | 0.49 | 0.93 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 |
| FII | 4.6 | 5.5 | 5.85 | 6.2 | 7.2 | 9.34 | 8.9 | 8.8 | 8.61 | 8.7 |
| DII | 6.31 | 6.91 | 6.63 | 4.27 | 3.86 | 2.55 | 3.13 | 3.51 | 3.67 | 2.35 |
| Public | 29.77 | 28.26 | 28.19 | 30.21 | 29.62 | 28.79 | 28.65 | 28.37 | 28.4 | 29.62 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 |
| FII | 0.72 | 0.86 | 0.92 | 0.97 | 1.13 | 1.46 | 1.39 | 1.38 | 1.35 | 1.36 |
| DII | 0.99 | 1.08 | 1.04 | 0.67 | 0.61 | 0.4 | 0.49 | 0.55 | 0.58 | 0.37 |
| Public | 4.67 | 4.43 | 4.42 | 4.74 | 4.64 | 4.51 | 4.49 | 4.45 | 4.45 | 4.64 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.68 | 15.68 | 15.68 | 15.68 | 15.68 | 15.68 | 15.68 | 15.68 | 15.68 | 15.68 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
